

**PLEASE NOTE:** This trial has been registered retrospectively.

## Trial Description

### Title

**Focal therapy of prostate cancer using mpMRI/TRUS-guided high intensity focused ultrasound (HIFU) technology: a prospective register study (FOXPRO\_REGISTER)**

### Trial Acronym

**FOXPRO\_REGISTER**

### URL of the trial

<http://none>

### Brief Summary in Lay Language

**Prospective register study to evaluate if focal therapy of prostate cancer using mpMRI/TRUS-guided HIFU represents a therapy alternative for localized prostate cancer in patients who refuse guideline conform prostate cancer treatment. We hypothesis that a local cancer control can be achieved.**

### Brief Summary in Scientific Language

**Focal therapies for localized prostate cancer are described in recent guidelines to be the therapeutic approach with the most important future potential in treatment. Focal therapy through HIFU focuses conglomeration of ultrasound waves on a specific point in the prostate and leads through overheating to protein denaturation and necrosis. The latest HIFU device for the first time utilizes the fusion of mpMRI and trans-rectal ultrasound (TRUS) imaging. Due to a high negative predictive value for mpMRI, it is used in combination with a mpMRI/TRUS-guided biopsy to decide which areas should not be treated. The optimized mpMRI/TRUS-HIFU approach has potentially less morbidities than described whole gland treatment options. This mpMRI/TRUS HIFU technology holds great promise to progressively revolutionize the efficacy and safety of PCA treatment in selected patients.**

## Organizational Data

- DRKS-ID: **DRKS00009021**
- Date of Registration in DRKS: **2015/10/19**
- Date of Registration in Partner Registry or other Primary Registry: [---]\*
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **Approved**
- (leading) Ethics Committee Nr.: **2015-401M-MA-§ 23b MPG , Medizinische Ethik-**



DRKS-ID: **DRKS00009021**

Date of Registration in DRKS: **2015/10/19**

Date of Registration in Partner Registry or other Primary Registry: [---]\*

Investigator Sponsored/Initiated Trial (IST/IIT): **yes**

Ethics Approval/Approval of the Ethics Committee: **Approved**

**Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg**

## Secondary IDs

- Universal Trial Number (UTN): **U1111-1172-9491**

## Health condition or Problem studied

- ICD10: **C61 - Malignant neoplasm of prostate**

## Interventions/Observational Groups

- Arm 1: - **Focal ablation of prostate cancer lesion or lesions within the prostate using multiparametricMRI/ transrectal-ultrasound(TRUS)-guided HIFU (device: FocalOne®, EDAP TMS GmbH, France) after diagnosis with a 12-core prostate biopsy or targeted biopsy of the prostate using mpMRI imaging - 12 months post-therapy control biopsy of prostate using multiparametricMRI/transrectal-ultrasound(TRUS)-fused prostatic biopsy**

## Characteristics

- Study Type: **Interventional**
- Study Type Non-Interventional: [---]\*
- Allocation: **Single arm study**
- Blinding: [---]\*
- Who is blinded: [---]\*
- Control: **Uncontrolled/Single arm**
- Purpose: **Treatment**
- Assignment: **Single (group)**
- Phase: **N/A**
- Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **N/A**

### Primary Outcome

**Focal ablation of prostate cancer with negative mpMRI/TRUS fused biopsy at 12 mo after treatment\***

**\*in case of contraindications against a MRI: ultrasound-guided only**

### Secondary Outcome

**Secondary treatment free time**

**Biochemical treatment failure**

**Metastatic-free survival**

**Cancer-specific mortality**

**Overall mortality**

**Functional outcome**

**Clinical validity of mpMRI to analyse the presence of residual or recurrent cancer compared with histopathologic findings using control biopsy\***

**\*if no contraindications against a MRI**

**Assessment of safety:**

**60-day postoperative complications using Clavien-Dingo grading system**

### Countries of recruitment

- **DE Germany**

### Locations of Recruitment

- University Medical Center **Klinik für Urologie, Mannheim**

### Recruitment

- Planned/Actual: **Actual**
- (Anticipated or Actual) Date of First Enrollment: **2015/09/09**
- Target Sample Size: **50**
- Monocenter/Multicenter trial: **Monocenter trial**
- National/International: **National**

### Inclusion Criteria

- Gender: **Male**
- Minimum Age: **18 Years**
- Maximum Age: **no maximum age**

### Additional Inclusion Criteria

- **refusion of guideline conform prostate cancer therapy**
- **serum PSA: PSA  $\leq$  30 ng/ml**
- **mpMRT/TRUS bioptic proven prostate cancer:**  
**Clinical stage: localized**
- **No inclusion into trial FOXPRO or FOXPRO\_RAD possible**

### Exclusion criteria

**acute urinary tract infection; lymph node or bone metastasis**

### Addresses

#### ■ Primary Sponsor

**Klinik für Urologie, Universitätsmedizin Mannheim**  
**Mr. PD Dr. med. Manuel Ritter**  
**Theodor-Kutzer-Ufer 1-3**  
**68167 Mannheim**  
**Germany**

Telephone: **0621-3832215**

Fax: [---]\*

E-mail: [---]\*

URL: [---]\*

#### ■ Contact for Scientific Queries

**Klinik für Urologie, Universitätsmedizin Mannheim**  
**Mr. PD Dr. med. Manuel Ritter**  
**Theodor-Kutzer-Ufer 1-3**  
**68167 Mannheim**  
**Germany**

Telephone: **0621-3832215**

Fax: [---]\*

E-mail: **manuel.ritter at medma.uni-heidelberg.de**

URL: [---]\*

#### ■ Contact for Public Queries

**Klinik für Urologie, Universitätsmedizin Mannheim**  
**Mr. PD Dr. med. Manuel Ritter**  
**Theodor-Kutzer-Ufer 1-3**  
**68167 Mannheim**  
**Germany**

Telephone: **0621-3832215**

Fax: [---]\*

E-mail: **manuel.ritter at medma.uni-heidelberg.de**



### **Contact for Public Queries**

**Klinik für Urologie, Universitätsmedizin Mannheim**  
**Mr. PD Dr. med. Manuel Ritter**  
**Theodor-Kutzer-Ufer 1-3**  
**68167 Mannheim**  
**Germany**

Telephone: **0621-3832215**

Fax: [---]\*

E-mail: **manuel.ritter at medma.uni-heidelberg.de**

URL: [---]\*

### ■ **Contact for Public Queries**

**Universitätsmedizin Mannheim, Klinik für Urologie**  
**Mr. Dr. med. Jost von Hardenberg**  
**Theodor-Kutzner-Ufer 1-3**  
**68167 Mannheim**  
**Germany**

Telephone: **06213832215**

Fax: [---]\*

E-mail: **jost.vonhardenberg at medma.uni-heidelberg.de**

URL: [---]\*

### ■ **Contact for Scientific Queries**

**Universitätsmedizin Mannheim, Klinik für Urologie**  
**Mr. Dr. med. Jost von Hardenberg**  
**Theodor-Kutzner-Ufer 1-3**  
**68167 Mannheim**  
**Germany**

Telephone: **06213832215**

Fax: [---]\*

E-mail: **jost.vonhardenberg at medma.uni-heidelberg.de**

URL: [---]\*

## **Sources of Monetary or Material Support**

### ■ **Private sponsorship (foundations, study societies, etc.)**

**H.W. & J. Hector-Stiftung zu WeinheimHerr Senator e.h. Dr. h.c. Hans-Werner Hector**  
**Mr.**  
**Elisabethstraße 9**  
**68165 Mannheim**  
**Germany**

DRKS-ID: **DRKS00009021**

Date of Registration in DRKS: **2015/10/19**

Date of Registration in Partner Registry or other Primary Registry: [---]\*



Deutsches Register  
Klinischer Studien

German Clinical  
Trials Register

---

**Private sponsorship (foundations, study societies, etc.)**

**H.W. & J. Hector-Stiftung zu WeinheimHerr Senator e.h. Dr. h.c. Hans-Werner Hector  
Mr.**

**Elisabethstraße 9  
68165 Mannheim  
Germany**

Telephone: [---]\*

Fax: [---]\*

E-mail: [---]\*

URL: [---]\*

## Status

- Recruitment Status: **Recruiting ongoing**
- Study Closing (LPLV): [---]\*

## Trial Publications, Results and other documents

*Please note:*

*There are additional attributes available concerning this trial. To open an extended view please [click here](#).*